Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …

T Payen, J Trédaniel, L Moreau, S Larivé… - … Medicine and Research, 2021 - Elsevier
Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …
被引用次数：8 相关文章

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …

T Payen, J Trédaniel, L Moreau… - Respiratory …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …

T Payen, J Trédaniel, L Moreau, S Larivé… - Respiratory Medicine …, 2020 - europepmc.org
Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …